Plus Therapeutics, Inc. (PSTV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
4200 Marathon Boulevard
Austin, TX 78756
United States of America (the)
Phone
737 255 7194
Sector
Healthcare
Industry
Biotechnology
Employees
21
First IPO Date
July 11, 2001
| Name | Title | Pay | Year Born |
| Marc H. Hedrick | President, Chief Executive Officer & Director | 934,244 | 1963 |
| Andrew J. Sims | Vice President & Chief Financial Officer | 556,737 | 1973 |
| Russ Havranek | Executive Vice President of Commercial and Corporate Strategy | 0 | N/A |
| Desiree Smith | Corporate Controller | 0 | 1964 |
| Russell W. Bradley | President & GM of CNSide Diagnostics, LLC | 0 | 1964 |
| Eric J. Daniels | Chief Development Officer | 0 | 1973 |
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.